Certification Period. The time period during which a Participant is eligible for WIC Services based on his/her application for those WIC Services.
Certification Period. Certifications expire 36 months from the date that the Program certification requirements are met by a candidate. Candidates must meet Certification renewal requirements prior to the expiration date of their certification in order to maintain active certification. If Certification renewal requirements are not met before the expiration date, Certification will be deemed revoked without further action by The Linux Foundation and this Agreement shall terminate effective as of the expiration date, subject to the provisions of Section 12.3.
Certification Period. The period of time specified by MISMO in its sole discretion that the certification of a particular unmodified Certified Product will remain in effect before re-certification is required.
Certification Period. LFCS certifications awarded on or after 04/10/18, and LFCE certifications awarded on or after 06/10/18, expire 36 months from the date that the Program certification requirements are met by a candidate. All other certifications expire 24 months from the date the program certification requirements were met by a candidate. Candidates must meet Certification renewal requirements prior to the expiration date of their certification in order to maintain active certification. If certification renewal requirements are not met before the expiration date, Certification will be revoked and this Agreement will be terminated, subject to the provisions of Section 12.3.
Certification Period. 3.1 During the Certification Period, Mylan will exert its continuing best efforts, at its expense, to prosecute the ANDA(s) for the Designated Product (in all CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS the contemplated dosage strengths) filed hereunder successfully to the granting of an FDA approval to market the Designated Product. Penwest will, promptly and throughout the Certification Period, provide to Mylan all necessary information in or coming into Penwest's possession or reasonably available to it for such purpose. Each party understands and agrees that the other does not warrant or commit that the Designated Product will be successfully licensed or certified for marketing by the FDA, and neither party shall have any liability or responsibility to the other or to third parties for any such failure of the certification process hereunder, except to the extent such failure results from said party's intentional misconduct, negligence, or breach of its duties or obligations as set forth herein.
3.2 Either party may terminate this Agreement before completion of the Certification Period by delivery of 90 days' written notice to the other if such party reasonably determines that, due to unfavorable action by the FDA, the ANDA is not likely to be approved by the FDA, regardless of any further steps or submissions that could be made.
3.3 Mylan's Project Contact will provide written reports to Penwest's Project Contact at least quarterly throughout the Certification Period, stating in detail all efforts made and in process, and all significant progress achieved and difficulties encountered in the certification effort since the last such report. Mylan's Project Contact will also be available throughout the Certification Period to answer any reasonable questions from Penwest's Project Contact.
Certification Period. Under the 2014 QI Agreement and the Proposed QI Agreement, the initial certification period ends at the end of the third full calendar year that the agreement is in effect. Each subsequent certification period is three full calendar years thereafter. A comment to the Proposed QI Agreement requested that the initial certification period be shortened and/or the second certification period be extended, so that the initial certification period would end on December 31, 2016, the termination date of the 2014 QI Agreement. Because the certification periods include any renewals of the QI agreement, it is not necessary that the certification period and an interim termination date be the same. In addition, the proposed solution fails to address cases of those QIs that had QI agreements with effective dates in 2015 and 2016. As a result, the 2017 QI Agreement does not incorporate this change. Another comment to the Proposed QI Agreement requested that a QI be allowed to apply the provisions of the 2014 QI Agreement to its initial certification period for purposes of making the initial periodic certification of compliance and providing the factual information required. This comment was not adopted because the 2014 QI Agreement, unlike the 2017 QI Agreement, does not contain compliance provisions and requirements specific enough for a QI to apply that agreement to its initial compliance period and provide the factual information required with the periodic certification. With respect to the requirement in Part II.F of Appendix I of the Proposed QI Agreement that a QI certify to its FATCA status, a comment requested clarification whether the requirement that the QI certify to its FATCA status over the certification period meant certification period or calendar year. As having an appropriate FATCA status is a prerequisite to enter into a QI agreement and to maintain the agreement, a QI is required to certify to its FATCA status for the entire certification period and not just the calendar year selected for the periodic review.
Certification Period. 3.1 During the Certification Period with respect to the United States, Schwxxx Xxxrma will exert its continuing best efforts, at its expense, to prepare and file an ANDA or ANDAs for the Designated Products with the FDA and to prosecute the same successfully to the granting of an FDA license to market the Designated Product in both of the dosage strengths. TIMERx Technologies will, promptly and throughout the Certification Period, provide to Schwxxx Xxxrma all necessary information in or coming into TIMERx Technologies' possession or reasonably available to it for such purpose. Also, during the Certification Period, ********************************************************* ************************.
3.2 Schwxxx Xxxrma shall exert its continuing best efforts to conduct or arrange for, at Schwxxx Xxxrma's expense, all further testing and studies during the Certification Period, including as to efficacy, bioavailability, bioequivalence, and safety and toxicology, in connection with the development, licensing, manufacture and marketing of the Designated Product, and for compliance with all requirements imposed by the government of the United States with respect to the Designated Products, and, if there is a Certification Period for Canada and/or Mexico pursuant to Section 3.3, also as imposed by the government of such nation(s). TIMERx Technologies will, promptly and throughout the Certification Period, provide to Schwxxx Xxxrma all necessary information in or coming into TIMERx Technologies' possession or reasonably available to it for such purpose.
3.3 If, at any time or times during the License Period, TIMERx Technologies reasonably demonstrates to Schwxxx Xxxrma that
(i) Covera-HS or an AB bioequivalent to it has been approved for marketing in Canada or Mexico, or such approval has been applied for and is reasonably likely to be granted; and
(ii) TIMERx Technologies or a third party is interested in good faith in undertaking to market the Designated Product in such nation pursuant to the equivalent of an ANDA in such nation, then TIMERx Technologies shall afford Schwxxx Xxxrma a period of 60 days in which to agree that a Certification Period with respect to such nation, and governed by this Section 3, shall commence hereunder, during which Schwxxx Xxxrma will exert its continuing best efforts, at its expense, to prepare and file such ANDA-equivalent applications for the Designated Products with the regulatory authorities in such nation, and to prosecute the...
Certification Period. 3.1 During the Certification Period with respect to the United States, Schwxxx Xxxrma will exert its continuing best efforts, at its expense, to prepare and file an ANDA or ANDAs for the Designated Products with the FDA and to prosecute the same successfully to the granting of an FDA license to market the Designated Product in each of the four dosage strengths. TIMERx Technologies will, promptly and throughout the Certification Period, provide to Schwxxx Xxxrma all necessary information in or coming into TIMERx Technologies' possession or reasonably available to it for such purpose. Also, during the Certification Period, TIMERx Technologies will exert its continuing best efforts to qualify the manufacturing sites referred to in Section 5.2 for the manufacture of Formulated TIMERx.
Certification Period. 4.1 Your certification will be valid for three-year periods, beginning on the date of your first successful assessment.
4.2 You must ensure continuous certification. You will therefore need to ensure that you have engaged an assessor and allowed sufficient time for the assessment to be undertaken in accordance with paragraph 3, prior to the expiry of your certification.
Certification Period. Casual collectors shall be certified for periods not to exceed six (6) months, ending on June 30th and December 31st of each year, at the end of which they shall be evaluated on the basis of their performance and the AUTHORITY'S need for their services. Re-certification shall be at the AUTHORITY'S discretion. After the completion of thirty (30) consecutive months of employment during which a Casual collector has received a satisfactory or above evaluation, the employee will no longer be subject to the six months recertification.
